{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-004997","form_type":"8-K","ticker":null,"cik":"0001621227","company_name":"Adaptimmune Therapeutics PLC","filed_at":"2024-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.286483+00:00","generated_at":"2026-06-03T23:24:21.714212+00:00","sec_items":["1.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adaptimmune-Genentech allogeneic T-cell collaboration terminated; focus on afami-cel PDUFA Aug 4","bullets":["Genentech terminates 2021 collaboration on allogeneic T-cell therapies; termination effective ~Oct 7, 2024.","Adaptimmune received $150M upfront and $35M milestones; no further milestones or payments due.","Company reaffirms focus on afami-cel launch; PDUFA target date August 4, 2024; Investor Day April 18.","Adaptimmune retains all rights to its iPSC-based allogeneic platform and autologous pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-004997","json":"https://secwatch.observer/filing/0001558370-24-004997.json","markdown":"https://secwatch.observer/filing/0001558370-24-004997.md","text":"https://secwatch.observer/filing/0001558370-24-004997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024004997/0001558370-24-004997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024004997/adap-20240410x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T23:24:21.714212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0610dbe5874babdf3cba59764c2490a5b047714a","claim":"Adaptimmune Therapeutics PLC terminated Strategic Collaboration and License Agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd. (effective 2024-04-10).","evidence_excerpt":"On April 10, 2024, Adaptimmune Limited, a wholly-owned subsidiary of Adaptimmune Therapeutics plc (“Adaptimmune”) received notice of termination of the Strategic Collaboration and License Agreement with Genentech, Inc. (“Genentech”) and F. Hoffman-La Roche Ltd. (the “Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024004997/0001558370-24-004997-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Genentech, Inc. and F. Hoffman-La Roche Ltd."},{"label":"Effective","value":"2024-04-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}